In an Australasian BioTechnology article, Facilities for a Strong Future, Emerson’s Michalle Adkins and Makarand Mujumdar share how pharmaceutical and biotech manufacturers can improve local capacity to meet the needs of the regions in which they operate.
There are four core pillars we look to address in order to support pharmaceutical and biopharmaceutical manufacturers in achieving line and facility efficiency goals.
Reliability of assets used in the manufacturing process is paramount for safe, efficient and effective operations. Unplanned asset failures, improper asset performance, poor maintenance planning, and untimely follow-through can cause shutdowns, under-utilized production equipment, deviations, or material/product losses.
Initiating Good Manufacturing Practices (GMP) production operations, whether as part of facility start-up, product changeover, or following a shutdown, requires complex coordination of both logical and physical process controls. Inefficient configuration and qualification practices for automation and information management systems can lead to both start-up delays and productivity losses.
Neo Chow Yang shares how Emerson’s Real-Time Modeling System allows users to visualize the facility constraints, accommodate variability, maximize production, and understand the implications of any change in the manufacturing process.
For manufacturers in the Life Sciences industry, production challenges often occur in these four areas—production readiness, equipment reliability, personnel effectiveness and facility/line efficiency. In this post, I’ll focus on equipment reliability, and specifically, unplanned downtime.
Flow is the foundation of world class production processes. Impediments to flow result in waste (transportation, inventory, motion, waiting, over-processing, over-production, defects). Unfortunately, digital solutions are often leveraged to address observed wastes in production processes without first addressing foundational problems.
In a presentation at the ACHEMA Pulse virtual conference this year, Emerson’s Alan Johnston shared how fast rollout of COVID vaccine manufacturing has changed the mindset of how quickly a new therapy can move from development to commercial manufacturing and ultimately to the consumer.
Accelerating vaccine development requires unprecedented flexibility in managing data. With increasing integration between product lifecycle management systems and software—like distributed control systems (DCS) and manufacturing execution systems (MES)—data, recipes, and processes can be digitally altered, shared, and used to scale across the lifecycle.
Technology has continued to advance and provide ways to assist pharmaceutical & biopharmaceutical manufacturers with production readiness. Improper set up and qualification of automation and information management production applications cause start-up and product changeover delays, as well as slow performance during production runs.
At Texas A&M University’s Mary Kay O’Connor Process Safety Center’s 76th Instrumentation and Automation Symposium, Emerson’s Greg McMillan presented on Bioreactor Control and Optimization using Digital Twin technology.
A common theme across the Emerson Exchange Virtual Series has been the way software and digital technologies have helped us all deal with an unexpected and unprecedented pandemic. Wherever there is adversity, there are also innovators who step up to the challenge of...
Stay up to Date with the Latest News and Updates
Subscribe for Updates
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Our Global Community